This economic evaluation estimates the cost-effectiveness of prevention strategies for ovarian and breast cancer among individuals with pathogenic variants in cancer susceptibility genes BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BRIP1. This evidence concerns the gene BRCA2 and breast carcinoma.